This case highlights a clinically significant episode of euDKA in a patient with newly diagnosed T2DM who was initiated on combination therapy with a GLP-1RA and an SGLT2 inhibitor. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.